News & Updates
Showing Pharmacy articles
Showing
Retifanlimab plus chemo improves survival in metastatic NSCLC
The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
Palbociclib plus ET prolongs survival in metastatic breast cancer
First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.
T-DXd improves PFS in breast cancer with rapid progression
Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.
